Login
Who's Online
We have 117 guests and no members online
Statistics
- Users 5524
- Articles 734
- Articles View Hits 17121643
Why Use This Site for Advertisement?
Thank you for your interest in advertising on Gene Therapy Net. The website is active since January 2008 and the site's traffic grows day by day (see statistics). The visitors of Gene Therapy Net are professionals, doctors and researchers, as well as students, patients, regulatory affairs officers, government policy officers, and everyone else interested in gene therapy. |
|
Gene Therapy Net is run by a policy officer in the clinical gene therapy trial assessment procedure in the Netherlands. He has a scientific background in molecular biology and immunology. The website is a non-governmental, personal initiative and is aimed to provide comprehensive and accurate information about gene therapy, clinical trials, research news, and relevant gene therapy regulation and legislation. |
Advertisement Opportunities
Full banners, cube banners and text ads will be placed on highly visible sections throughout the site. Cube banners and text ads are placed in the left columns of the site, whereas full banners are placed in the middle wide column of the site. Your banner or text ad will be hyperlinked to the web address of your choice.
There are four different types of campaigns:
1 | Full banner | Located in rotation with other banners on all pages, including the home page |
2 | Home page banner or text links | Located only on the home page. Always visible in 1st or 2nd news item in center of the home page |
3 | Cube banner | Located on left ‘related links’ column on a minimum of 50% of all pages, including the home page |
4 | Text links | Located on left ‘related links’ column on a minimum of 50% of all pages, including the home page |
Advertisement Rates
We suggest a minimum of 3 months or at least 10,000 impressions, but please keep in mind that these rates and time lengths are not set in stone, but rather displayed to give you an idea on how our ad pricing is usually structured. By advertising on Gene Therapy Net, you agree to our terms and conditions listed below.
Contact us for more information about advertising.
Advertising Terms and Conditions: All ads are reviewed for correct usage, and must be approved prior to publication. Gene Therapy Net reserves the right to refuse advertising privileges to any web site for any reason, including the promotion of pornographic products and/or content, the advocating of illegal activities, immoral conduct, plagiarism, cheating, etc. Gene Therapy Net shall not be held responsible for grammatical errors, typographical errors, or errors in artwork provided by the advertiser. All ads are at the discretion of Gene Therapy Net. All rates are agreed on before advertisement is placed. Your ad will be place after full payment has been received. When an order has been received and payment taken for the service there will be no refund to the advertiser. Gene Therapy Net reserves the right to modify, change or otherwise improve upon the design and format of any or all of its pages at any time without notice. Gene Therapy Net reserves the right to modify, eradicate and/or change any or all of these terms and conditions without notice, including the right to change the above rates or to terminate this advertising program. We appreciate, but do not require, reciprocal links to Gene Therapy Net to be posted on your site.
Suggestions
Gene Therapy News
- Libya signs contract with UAE for gene therapy treatment of children with spinal muscular atrophy - Libya Herald
Sun, 08 Dec 2024 12:31:1 GMT - A sickle cell first: Base editing, a new form of gene therapy, leaves patient feeling 'more than fine' - Medical Xpress
Sat, 07 Dec 2024 18:24:2 GMT - Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult H - Business Wire
Sat, 07 Dec 2024 18:00:0 GMT - Beam Therapeutics Reports Breakthrough Clinical Data for Sickle Cell Gene Therapy BEAM-101 - StockTitan
Sat, 07 Dec 2024 17:30:0 GMT - New Preclinical Data Demonstrate Potential of Capsida's IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations - PR Newswire
Fri, 06 Dec 2024 18:00:0 GMT - Cell and gene therapy companies must demonstrate strong value proposition for investment - Yahoo Finance
Fri, 06 Dec 2024 17:51:3 GMT - New CMS Payment Model Launched for Sickle Cell Gene Therapy - Inside Precision Medicine
Fri, 06 Dec 2024 16:46:2 GMT - Advancing Hope: AFTD Develops New Gene Therapy Resource - AFTD
Fri, 06 Dec 2024 15:00:0 GMT - Beacon reports early success in XLRP gene therapy trial - Investing.com
Fri, 06 Dec 2024 13:15:4 GMT - Children’s Hospital Los Angeles Celebrates 100th Retinal Gene Therapy Procedure - Business Wire
Fri, 06 Dec 2024 12:00:0 GMT - New gene therapy shows promise in preventing premature births - News-Medical.Net
Fri, 06 Dec 2024 04:05:0 GMT - Nanoparticle-mediated gene therapy fixes major cause of stillbirth and premature birth in guinea pig model - Phys.org
Thu, 05 Dec 2024 22:32:4 GMT - Kanglin raises $20M to advance sickle cell gene therapy KL003 - Sickle Cell Disease News
Thu, 05 Dec 2024 18:13:1 GMT - Cell and gene therapy access model launches in US - BioPharma-Reporter.com
Thu, 05 Dec 2024 14:50:5 GMT - Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer - Yahoo Finance
Thu, 05 Dec 2024 13:00:0 GMT